Preclinical News and Research

RSS

Zengen announces positive results of treatment for vaginal yeast infection

Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.

25 May 2004

Pharmaceutical agreement involving novel obesity compound

Bristol-Myers Squibb Company and Solvay Pharmaceuticals today announced that the companies have entered into a worldwide agreement for the Solvay compound SLV319, which is currently in Phase I development with potential for use in treating obesity and other metabolic disorders.

17 May 2004

Genetically engineered viruses may create new class of cancer therapies

A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.

15 May 2004

Viragen and University of Miami to advance anti-cancer study

Viragen, Inc. today announced that the Company extended its agreement with the University of Miami and UM/Sylvester Comprehensive Cancer Center to develop a novel form of an immune enhancing drug (IEP 11) that has shown promise in animal studies by inhibiting tumor growth in a broad range of cancers.

12 May 2004

Nanobodies herald a new era in cancer therapy

Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects.

12 May 2004

A second-generation targetted antibody for potential cancer therapy

The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry.

6 May 2004

Research into Chinese herbal medicine Qian Ceng Ta may help Alzheimer’s

Georgetown University Medical Center researchers today opened a new clinical trial designed to test if huperzine A, a natural product derived from a Chinese herb, can slow down or prevent cognitive decline in patients with mild to moderate Alzheimer’s Disease (AD).

6 May 2004

World's first gene therapy trial aimed at preventing cancer

The concept seems straightforward. If, at its heart, cancer is a disease of genes, then giving patients new genes should disarm cancer. Such treatment would replace missing or faulty genes that keep cell growth in check, or would flush the body with "super genes" that could attack and destroy cancer.

5 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

New hope for advances in treatment methods for AIDS, Alzheimer's and age-related blindness

Pharmaceutical science leaders from the FDA, research institutions and top pharmaceutical companies will gather at the 2004 AAPS National Biotechnology Conference, AAPS' spring annual meeting.

4 May 2004

Funding for new biomaterials for spinal disc repair and regeneration

Orthonics, Inc., an Atlanta start-up company developing new biomaterials for spinal disc repair and regeneration, has received initial funding from Viscogliosi Brothers, LLC, a New York-based closely held venture capital/private equity and merchant banking firm focused on the musculoskeletal/orthopedics industry. Terms of the funding were not disclosed.

30 Apr 2004

Functional genomics and proteomics may accelerate the discovery of new drugs and therapeutic molecules

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.

29 Apr 2004

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

AGT Biosciences Limited of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California, today announced that they have signed a merger agreement. The cross-border merger creates a new, genomics-driven pharmaceutical company with leading edge capabilities for drug discovery and development, as well as two drug candidates in Phase II human trials for cancer.

28 Apr 2004

SARS antibody sent to China

Responding to a request from a Chinese biotechnology company working closely with officials in China, Medarex, Inc. and the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) have shipped to Beijing a sample of the fully human antibody to SARS developed by Medarex and MBL/UMMS.

26 Apr 2004

New developments in the treatment of pancreatic cancer

A booster dose of a substance already found in the body appears to be safe and non-toxic for the treatment of pancreatic cancer, and shows signs of arresting pancreatic cancer cell growth in patients, Penn State College of Medicine researchers report.

20 Apr 2004

Functional genomics provide improved drug discovery

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.

20 Apr 2004

Myriad Genetics advances drug for chemotherapy-induced nausea

Myriad Genetics, Inc. today released new data on MPC-4505, its Neurokinin-1 (NK1) receptor antagonist, a drug candidate for chemotherapy-induced nausea and vomiting (emesis). MPC-4505 is a potent, orally bioavailable, CNS-penetrating, highly selective NK1 antagonist.

20 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Cancer-specific protein offers new target for the development of melanoma vaccine

Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine. SSX-2 is the prototype of the SSX family, and is part of a larger group of proteins known as cancer/testis (CT) antigens.

16 Apr 2004

Gene therapy helps damaged heart cells regain strength and beat normally

Researchers at Jefferson Medical College and Duke University have used gene therapy to help damaged heart cells regain strength and beat normally again in the laboratory. The work takes the scientists one step closer to eventual clinical trials in humans.

12 Apr 2004

Preclinical News and Research

Zengen announces positive results of treatment for vaginal yeast infection

Pharmaceutical agreement involving novel obesity compound

Genetically engineered viruses may create new class of cancer therapies

Viragen and University of Miami to advance anti-cancer study

Nanobodies herald a new era in cancer therapy

A second-generation targetted antibody for potential cancer therapy

Research into Chinese herbal medicine Qian Ceng Ta may help Alzheimer’s

World's first gene therapy trial aimed at preventing cancer

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

New hope for advances in treatment methods for AIDS, Alzheimer's and age-related blindness

Funding for new biomaterials for spinal disc repair and regeneration

Functional genomics and proteomics may accelerate the discovery of new drugs and therapeutic molecules

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

SARS antibody sent to China

New developments in the treatment of pancreatic cancer

Functional genomics provide improved drug discovery

Myriad Genetics advances drug for chemotherapy-induced nausea

Preclinical data on Histamine's ability to prevent liver damage

Cancer-specific protein offers new target for the development of melanoma vaccine

Gene therapy helps damaged heart cells regain strength and beat normally

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News